Argus Lowers Gilead Sciences, Inc. (GILD) to Hold

Argus cut shares of Gilead Sciences, Inc. (NASDAQ:GILD) from a buy rating to a hold rating in a research note released on Monday, MarketBeat reports. Argus currently has $73.77 target price on the biopharmaceutical company’s stock, up from their previous target price of $73.25.

GILD has been the topic of several other reports. BidaskClub downgraded Gilead Sciences from a buy rating to a hold rating in a research note on Wednesday, August 9th. Vetr downgraded Gilead Sciences from a strong-buy rating to a buy rating and set a $82.15 target price on the stock. in a research note on Monday, August 28th. Wells Fargo & Company lifted their target price on Gilead Sciences from $73.00 to $81.00 and gave the company a market perform rating in a research note on Wednesday, September 6th. Oppenheimer Holdings, Inc. assumed coverage on Gilead Sciences in a research note on Thursday, October 5th. They issued a market perform rating on the stock. Finally, Deutsche Bank AG reiterated a buy rating and issued a $81.00 target price (up from $79.00) on shares of Gilead Sciences in a research note on Thursday, July 27th. One investment analyst has rated the stock with a sell rating, twelve have assigned a hold rating, eighteen have issued a buy rating and one has assigned a strong buy rating to the company. The company currently has an average rating of Buy and an average target price of $84.87.

Gilead Sciences (NASDAQ GILD) traded up $0.66 during trading hours on Monday, reaching $71.81. The company had a trading volume of 8,539,300 shares, compared to its average volume of 9,360,801. The stock has a market cap of $93,690.00, a P/E ratio of 7.43, a PEG ratio of -1.19 and a beta of 1.13. The company has a quick ratio of 3.56, a current ratio of 3.68 and a debt-to-equity ratio of 1.10. Gilead Sciences has a 12-month low of $63.76 and a 12-month high of $86.27.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $2.27 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.13 by $0.14. The firm had revenue of $6.51 billion for the quarter, compared to the consensus estimate of $6.40 billion. Gilead Sciences had a return on equity of 57.15% and a net margin of 42.22%. The firm’s quarterly revenue was down 13.2% compared to the same quarter last year. During the same quarter last year, the business posted $2.75 EPS. equities research analysts predict that Gilead Sciences will post 8.53 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This news story was published by Markets Daily and is the sole property of of Markets Daily. If you are accessing this news story on another domain, it was stolen and reposted in violation of United States & international trademark and copyright law. The original version of this news story can be viewed at https://www.themarketsdaily.com/2017/11/16/argus-lowers-gilead-sciences-inc-gild-to-hold.html.

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, December 28th. Stockholders of record on Friday, December 15th will be given a $0.52 dividend. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.90%. The ex-dividend date is Thursday, December 14th. Gilead Sciences’s dividend payout ratio is currently 23.66%.

In other Gilead Sciences news, insider John F. Milligan sold 220,000 shares of the business’s stock in a transaction dated Monday, November 13th. The stock was sold at an average price of $72.88, for a total transaction of $16,033,600.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Gregg H. Alton sold 15,000 shares of the business’s stock in a transaction dated Wednesday, November 1st. The shares were sold at an average price of $74.82, for a total value of $1,122,300.00. Following the sale, the executive vice president now directly owns 77,363 shares of the company’s stock, valued at approximately $5,788,299.66. The disclosure for this sale can be found here. In the last ninety days, insiders sold 666,819 shares of company stock valued at $52,303,086. Company insiders own 1.30% of the company’s stock.

A number of hedge funds have recently bought and sold shares of GILD. Ray Gerald L & Associates Ltd. grew its position in Gilead Sciences by 11.0% during the first quarter. Ray Gerald L & Associates Ltd. now owns 75,025 shares of the biopharmaceutical company’s stock valued at $5,096,000 after acquiring an additional 7,445 shares during the period. Renaissance Group LLC lifted its stake in shares of Gilead Sciences by 8.2% during the first quarter. Renaissance Group LLC now owns 366,976 shares of the biopharmaceutical company’s stock worth $24,925,000 after purchasing an additional 27,760 shares in the last quarter. Nelson Roberts Investment Advisors LLC lifted its stake in shares of Gilead Sciences by 4.9% during the first quarter. Nelson Roberts Investment Advisors LLC now owns 76,737 shares of the biopharmaceutical company’s stock worth $5,212,000 after purchasing an additional 3,618 shares in the last quarter. Trust Co. of Vermont lifted its stake in shares of Gilead Sciences by 3.9% during the first quarter. Trust Co. of Vermont now owns 44,025 shares of the biopharmaceutical company’s stock worth $2,990,000 after purchasing an additional 1,644 shares in the last quarter. Finally, Xact Kapitalforvaltning AB lifted its stake in shares of Gilead Sciences by 4.5% during the first quarter. Xact Kapitalforvaltning AB now owns 216,347 shares of the biopharmaceutical company’s stock worth $14,694,000 after purchasing an additional 9,360 shares in the last quarter. 74.62% of the stock is owned by hedge funds and other institutional investors.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Analyst Recommendations for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply